TOTomas Olsson

Tomas Olsson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tomas Olsson has a total of 800 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment of multiple sclerosis with peptide-coupled red blood cells induces antigen-specific T regulatory cells

    by Andreas Lutterotti, Thomas Ludersdorfer, María José Docampo, Muriel Morax, Helen Hayward-Koennecke, Pietro Oldrati, Vasileia Kalaitzaki, Zoe Marti, Angela Zaugg, Mattias Bronge, et al.

    Inducing antigen-specific immune tolerance is a long-standing aim in organ-specific autoimmune diseases including multiple sclerosis (MS). We developed a therapy based on autologous red blood cells (RBCs) as tolerizing carriers of autoantigens and tested these in an open-label, dose-escalation, phase Ib clinical trial with clinical, imaging, and mechanistic readouts. RBCs coupled with seven immunodominant myelin peptides (pcRBCs) were safe and well tolerated. Several clinical and imaging readouts remained stable, which was supported by a reduction of neurofilament light chain indicating reduced tissue inflammation in the brain. Single-cell RNA sequencing identified expansion of antigen-specific CD4+ memory T cells with regulatory phenotypes and loss of proinflammatory cells three months after a single administration of pcRBCs. This was corroborated by a reduction of autoreactive CD4+ T cell responses and an early increase of IL-10, Tr1 regulatory T cells and tolerogenic monocytes and plasmacytoid dendritic cells. Biodistribution studies in mice and humans demonstrate that pcRBCs are rapidly processed by Kupffer cells in the liver and by marginal zone macrophages in the spleen. In summary, pcRBCs are a promising autologous cell therapy for achieving antigen-specific immune tolerance in MS.


  • Antibodies against MLC1 found in patients with NMOSD-like disease mediate astrocytopathy in rodent models

    by Hoi Kiu Wong, Samantha Ho, Qian Yu, Katherine S. Given, Dorina Shqau, Selia Baier, Stephan Winklmeier, Heike Rübsamen, Arek Kendirli, Kathrin Schanda, et al.

    The identification of autoantibodies against aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) has been essential in distinguishing neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody–associated disease (MOGAD) from classical multiple sclerosis (MS), with important implications for treatment. However, for several patients within this disease spectrum, the target of the autoimmune response remains unknown. Here, we describe the modulator of VRAC current 1 (MLC1), a membrane protein with extracellular epitopes enriched at astrocytic end feet, as an autoantigen. Serum MLC1 antibodies were verified with a cell-based assay, identifying four MLC1 immunoglobulin G (IgG)–positive patients among 297 patients with inflammatory autoimmune diseases of the central nervous system who were screened. All four MLC1 IgG–positive patients exhibited overlapping yet atypical clinical features of MS and NMOSD and tested negative for AQP4 and MOG antibodies. Moreover, treatment with a monoclonal MLC1 antibody induced astrocytopathy in mouse cerebellar slice cultures and in a rat encephalitis model. Thus, MLC1 antibodies identify a subset of patients with an NMOSD-like phenotype, underscoring their potential as a disease marker with pathogenic relevance.

  • Open Access

    Targeting progressive multiple sclerosis: Toward mechanism‐informed precision medicine

    by Fredrik Piehl, Gonçalo Castelo‐Branco, Maja Jagodic, Tomas Olsson

    Multiple sclerosis has undergone a therapeutic revolution over the past three decades. Randomized clinical trials and real‐world data demonstrate that modern disease‐modifying therapies substantially reduce relapse rates and acute inflammatory activity detected by magnetic resonance imaging (MRI). However, disability accumulation increasingly occurs independent of relapse activity, highlighting progression biology as the principal unmet need. Converging epidemiological and molecular evidence supports a pivotal role for Epstein–Barr virus (EBV) infection in disease initiation, whereas later stages appear dominated by brain‐intrinsic mechanisms, including compartmentalized inflammation, microglial activation, failure of remyelination and accelerated biological ageing. Population‐based cohorts demonstrate that early high‐efficacy therapy improves long‐term outcomes, yet the risk of progression rises markedly after midlife despite effective relapse suppression. Emerging biomarkers, such as serum neurofilament light chain, glial fibrillary acidic protein, paramagnetic rim lesions and advanced quantitative MRI metrics, now enable more granular monitoring of progressive pathology. Integration of imaging, fluid biomarkers, genetics and machine learning offers opportunities for individualized benefit–risk stratification. Brain‐penetrant Bruton's tyrosine kinase inhibitors, CD40 ligand‐targeting biologics, refined B‐cell‐depleting strategies and emerging chimeric antigen receptor T‐cell therapies represent promising approaches to target different aspects of compartmentalized inflammation and smoldering disease biology. Future management will require mechanism‐informed treatment algorithms that align therapeutic choice with dominant disease drivers while incorporating comorbidity management, de‐escalation strategies and potential EBV‐targeted preventive approaches to optimize outcomes across the entire disease course.


  • Open Access

    CSF Proteins Associated With Neuroaxonal Damage in Early Active Multiple Sclerosis

    by Felix Luessi, Chiara Starvaggi Cucuzza, Sinah Engel, Arda Civelek, Falk Steffen, Thomas Koeck, Philipp S. Wild, Ingrid Kockum, Tomas Olsson, Stefan Bittner, et al.

    The aim of this study was to identify biological processes associated with neuroaxonal degeneration in multiple sclerosis (MS) by analyzing protein patterns linked to neurofilament light (NfL) protein in CSF and serum samples. The highly sensitive proximity extension assay technology was used to quantify protein levels in paired CSF and serum samples from treatment-naïve, early-stage active MS patients (n = 114). The cohort was stratified into above and below median of CSF-NfL level. A discovery phase identified proteins upregulated in CSF, and a validation cohort (n = 128) confirmed findings in a more clinically diverse MS population, including patients receiving disease-modifying therapies. In the discovery cohort, 13 proteins were upregulated in CSF (leukocyte immunoglobulin like receptor B4, CXCL6, CXCL5, cluster of differentiation 38, CCL19, CXCL11, IMPA1, macrophage scavenger receptor 1 (MSR1), CXCL10, monocyte chemotactic protein 2, ITM2A, TNFRSF12A, and CCL23). It is important to note that associations with CCL19, CXCL11, MSR1, CXCL10, TNFRSF12A, and CCL23 were replicated in a validation MS cohort. By contrast, no consistent serum protein profiles associated with serum levels of NfL could be discerned in this group-based analysis. Furthermore, 75 CSF proteins showed a positive adjusted linear association with CSF-NfL, whereas no such significant association remained in the corresponding analysis in serum. The identified and replicated CSF protein profile indicates distinct inflammatory processes associated with ongoing neuroaxonal degeneration. All of these most robust 6 proinflammatory markers-CCL19, CXCL11, MSR1, CXCL10, TNFRSF12A, and CCL23-independently replicated and were individually observed to be relevant in the context of MS. These findings may further elucidate the immunologic pathways underlying disease processes leading to neuroaxonal degeneration.


  • Open Access

    Occupational Exposure to Industrial Dust and Rates of Multiple Sclerosis

    by Lars Alfredsson, Eva Johansson, Tomas Olsson, Pernilla Stridh, Anna Karin Hedström

    Exposure to lung irritants such as smoking and organic solvents has been associated with increased risk of multiple sclerosis (MS), particularly among genetically susceptible individuals. The aim of this study was to investigate the association between occupational exposure to industrial dust and MS and to assess potential interactions with smoking and HLA-DRB1*15:01. We conducted a Swedish population-based case-control study. Patients with incident MS age 16-70 years were consecutively identified by neurologists at 40 clinics (2005-2015). Eligibility criteria for participants were age 16-70 years, residence in Sweden, and a neurologist-confirmed diagnosis of MS according to the McDonald criteria. Controls without MS were randomly sampled from the national population register using density sampling and frequency-matched to cases on age, sex, and residential area. Occupational dust exposure was assessed using questionnaire data. Logistic regression was used to estimate odds ratios (ORs) and 95% CIs. Additive interactions between dust exposure and smoking and between dust exposure and HLA-DRB1*15:01 were assessed by calculating the attributable proportion (AP) due to interaction. An AP >0 is considered evidence of interaction. The analytic sample included 2,070 participants and 2,899 controls. The mean age at index was 34.4 years for participants and 35.4 years for controls. Women comprised 72.5% of participants and 75.1% of controls. Industrial dust exposure was associated with increased rate of MS (OR 1.30, 95% CI 1.05-1.63), with a dose-response relationship with duration (OR per 1-year exposure 1.03, 95% CI 1.00-1.06). Evidence of additive interactions was observed between dust exposure and smoking (AP 0.32, 95% CI 0.03-0.62) and between dust exposure and HLA-DRB1*15:01 (AP 0.25, 95% CI 0.002-0.52). Participants who smoked, were exposed to dust, and carried the HLA-DRB1*15:01 allele had an 11-fold increased rate of MS (OR 11.1, 95% CI 5.7-21.9), compared with those without any of these risk factors. Occupational dust exposure was associated with increased rate of MS, particularly in combination with smoking and HLA-DRB1*15:01, suggesting joint effects of occupational, environmental, and genetic risk factors. The reliance on self-reported occupational histories and potential residual confounding are important limitations. Further studies are warranted to clarify underlying mechanisms and to inform preventive strategies.


  • Open Access

    A susceptibility network analysis of disease trajectories leading to multiple sclerosis: A nationwide cohort study

    by Ali Ebrahimi, Uffe Kock Wiil, Tomas Olsson, Pietro Liò, Ingrid Kockum, Ali Manouchehrinia, Narsis A Kiani

    Background: The prodromal phase of multiple sclerosis (MS) is increasingly recognized, but most studies have focused on isolated symptoms or static comorbidity counts, leaving the evolving structure of pre-onset disease burden underexplored. Objective: To characterize dynamic disease trajectories preceding MS onset through longitudinal network modeling. Methods: Health data from 10,273 MS patients and 47,167 matched controls in Sweden were analyzed. Disease co-occurrence networks were constructed for three pre-onset windows (0–5, 5–10, 10–15 years), with comparisons of centrality, clustering, and path length. Rewiring scores captured structural shifts, while Markov clustering and trajectory mapping identified comorbidity communities. Results: MS networks were denser, more clustered, and showed shorter path lengths than controls, reflecting higher systemic interconnectivity. Psychiatric and metabolic diagnoses, especially depression, anxiety, diabetes, and abdominal pain, were hubs that gained prominence over time. Distinct clusters, including neuropsychiatric-toxicological and immune-endocrine constellations, were observed only in MS. Rewiring analysis revealed significant topological shifts in key diagnoses, such as inflammatory central nervous system disorders and substance use, as onset approached. Conclusions: MS is preceded by dynamic reorganization of the comorbidity landscape, marked by increasing connectivity and rewired hubs. This framework highlights systemic disruption before diagnosis and provides a novel, network-based tool for studying prodromes in complex disorders.


  • Open Access

    Anti-CD20 Therapy Induces a Persistent Suppression of EBV–Host Interactions in Multiple Sclerosis Despite B-Cell Repopulation

    by Chiara Starvaggi Cucuzza, Gavin Li, Olga Dethlefsen, Karin Byskata, Júlia Bort-Brusca, Mingming Li, Dimitri Guala, Chiara Sorini, Ewoud Ewing, Silvia D’oRso, et al.

    Emerging data supports a persistent immune reprogramming effect of B-cell-depleting therapies (BCDT) in relapsing-remitting multiple sclerosis (MS), although the underlying mechanisms are unknown. We performed immunologic and transcriptomic profiling of repopulating B cells, including single-cell RNA sequencing of paired naïve and memory B cells before and after rituximab (RTX), at a time when peripheral B-cell counts had normalized. Differential expression analysis revealed upregulation of NF-κB-associated genes across naïve and memory B-cell clusters, correlating with increased circulating B-cell activating factor (BAFF). In contrast, repopulating switched memory and atypical B cells showed marked downregulation of an Epstein-Barr virus (EBV) lytic-infection gene signature, accompanied by reduced T-cell activation to EBV antigens and to anoctamin-2, a candidate autoantigen. Our findings support a mechanistic link between active EBV replication in memory B cells and autoreactive T-cell responses, consistent with a model for MS disease activity centered on EBV-host interactions, which are durably suppressed by BCDT.

  • Top Cited Papers

    A human pan-disease blood atlas of the circulating proteome

    by María Bueno Álvez, Sofia Bergström, Josefin Kenrick, Emil Johansson, Mikael Åberg, Murat Akyildiz, Ozlem Altay, Hilda Sköld, Konstantinos Antonopoulos, Emmanouil Apostolakis, et al.

    The human blood proteome provides a holistic readout of health states through the assessment of thousands of circulating proteins. In this study, we present a pan-disease resource to enable the study of diverse disease phenotypes within a harmonized proteomics dataset. By profiling protein concentrations across 59 diseases and healthy cohorts, we identified proteins associated with age, sex, and body mass index, as well as disease-specific signatures. This study highlights shared and distinct protein patterns across conditions, demonstrating the power of a unified proteomics approach to uncover biological insights. The dataset, covering 8262 individuals and up to 5416 proteins, serves as an online resource for exploring disease-specific protein profiles and advancing precision medicine research.


  • Open Access

    Genetic Risk Variants for Multiple Sclerosis and Other Loci Linked to Intrathecal Immunoglobulin G Synthesis

    by Albert Pukaj, Adil Harroud, Klementy Shchetynsky, Laura Wirsching, Lucy Peters, Till F M Andlauer, Kimmo Pääkkönen, Steffan D Bos, Sinéad Moylett, Bénédicte Dubois, et al.

    Intrathecal synthesis of immunoglobulin G (IgG) is a key feature of multiple sclerosis (MS) and a prognostic marker for the disease course. Although previous studies identified 2 genetic regions-the major histocompatibility complex (MHC) region on chromosome 6 and the immunoglobulin heavy chain constant (IGHC) locus on chromosome 14-associated with intrathecal IgG synthesis in MS, the genetic underpinnings remain insufficiently understood. We conducted a genome-wide association study on intrathecal IgG synthesis using the IgG index to identify individuals with (≥0.7) or without (p = 1.48 × 10-8) in the sterile alpha motif domain containing 5 (SAMD5) gene on chromosome 6, with intrathecal IgG synthesis. We could confirm this association in a replication cohort (n = 1,094) and demonstrated that it is independent of a previously described association signal at the MHC region. In a subset (n = 1,413), we further identified rs1407 as a potential causal variant (p = 3.80 × 10-11, posterior inclusion probability = 0.92) for the previously reported association signal at the IGHC locus with the extent of intrathecal IgG synthesis. In addition, we demonstrated that a higher genetic burden for MS susceptibility, both within and outside of the MHC region, is associated with a higher likelihood of and a more pronounced intrathecal IgG synthesis. Our study revealed a previously unknown association between an intronic variant in SAMD5 with intrathecal IgG synthesis and identified a potential causal variant within the IGHC locus. It further provides evidence for possible effects of known MS risk variants on disease severity through their effect on the intrathecal humoral immune response, a prognostic marker for the disease course.